Nicola_K_photos / Shutterstock.com

30 April 2024NewsBiotechnologyLiz Hockley

Amgen and Sandoz settle dispute over blockbuster bone condition drugs

Agreement clears the way for Sandoz to launch denosumab biosimilars in May 2025 | Dispute over multiple patents covering Prolia and Xgeva resolved.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Amgen v Sanofi/Regeneron in Japan: Function, sequence, mechanism

19 March 2024 Amgen patents declared valid in Germany and Japan have also been deemed invalid by the European Patent Office, US Supreme Court, and in a separate Japan decision: but why? Takanori Abe of Abe & Partners examines the details.

Biotechnology

USPTO backs Wands factors post-Amgen enablement loss

11 January 2024 SCOTUS ignored Fed Circ cases and so-called Wands factors in reaching enablement decision | Pivotal question left unanswered | New guidance ‘provides clarity’ and reinforces status quo on enablement decisions.

More on this story

Amgen v Sanofi/Regeneron in Japan: Function, sequence, mechanism

19 March 2024 Amgen patents declared valid in Germany and Japan have also been deemed invalid by the European Patent Office, US Supreme Court, and in a separate Japan decision: but why? Takanori Abe of Abe & Partners examines the details.

Biotechnology

USPTO backs Wands factors post-Amgen enablement loss

11 January 2024 SCOTUS ignored Fed Circ cases and so-called Wands factors in reaching enablement decision | Pivotal question left unanswered | New guidance ‘provides clarity’ and reinforces status quo on enablement decisions.

More on this story

Amgen v Sanofi/Regeneron in Japan: Function, sequence, mechanism

19 March 2024 Amgen patents declared valid in Germany and Japan have also been deemed invalid by the European Patent Office, US Supreme Court, and in a separate Japan decision: but why? Takanori Abe of Abe & Partners examines the details.

Biotechnology

USPTO backs Wands factors post-Amgen enablement loss

11 January 2024 SCOTUS ignored Fed Circ cases and so-called Wands factors in reaching enablement decision | Pivotal question left unanswered | New guidance ‘provides clarity’ and reinforces status quo on enablement decisions.

More features

Gilead scores win in fake HIV drug dispute

Polsinelli grows roster with ex-corporate counsel

‘Don’t rely on national case law’ at the UPC: Wouter Pors, Bird & Bird

Sandoz wins $137.2m payout for lost profits in generic launch

Sanofi signs global rights deal to develop rare cancer therapy

Unified Patent Court visualised: Cases, divisions, and classes in charts

WBD to merge with firm to create ‘powerhouse’ practice

‘Be prepared, and don’t assume at the UPC’: Christopher Stothers